Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Submitted by admin on November 27, 2024 - 11:30am

Source:

Motley Fool

News Tags:

Headline:

snippet:

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide.
The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, Zepbound.
Rare disease drugs that Amgen acquired from Horizon Therapeutics could drive growth even if MariTide disappoints.

Search form